TDOC

+ Watchlist + Portfolio

Teladoc Health, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $6.66
52-Week Range: $4.40 – $9.89
Market Cap: $1.18B
P/E (TTM): —
EPS (TTM): -0.96
Dividend Yield: —

Advanced Metrics

Price/Book: 0.90
PEG Ratio: —
Return on Equity: -12.98%
Return on Assets: -3.22%
Gross Margin: 68.97%
Operating Margin: -5.68%
Profit Margin: -7.13%
Current Ratio: 0.83
Debt/Equity: 0.79
Total Debt: $1.04B
Free Cash Flow: $191.04M
Revenue Growth: -4.00%
Earnings Growth: —
Enterprise Value: $1.47B

TDOC Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$2.41B	$2.60B	$2.57B	$2.53B
Cost of Revenue	$743.99M	$760.03M	$751.27M	$771.59M
Gross Profit	$1.66B	$1.84B	$1.82B	$1.76B
Research & Development	$333.63M	$348.52M	$307.27M	$277.92M
Selling, General & Admin	$1.30B	$1.37B	$1.35B	$1.28B
Operating Expenses	$1.89B	$2.05B	$2.03B	$1.92B
Operating Income	-$227.37M	-$210.50M	-$208.79M	-$163.40M
EBITDA	-$13.37B	$151.40M	-$587.01M	$160.62M
Pretax Income	-$13.66B	-$219.61M	-$993.65M	-$235.53M
Income Tax	-$3.81M	$760.00K	$7.59M	-$35.21M
Net Income	-$13.66B	-$220.37M	-$1.00B	-$200.32M
Diluted EPS	-84.60	-1.34	-5.87	-1.14
Diluted Shares	161.46M	162.17M	170.56M	176.22M

TDOC Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$918.18M	$1.12B	$1.30B	$781.08M
Receivables	$235.65M	$230.06M	$223.96M	$201.66M
Inventory	$56.34M	$29.51M	$38.14M	$38.20M
Current Assets	$1.32B	$1.49B	$1.66B	$1.12B
Total Assets	$4.35B	$4.39B	$3.52B	$2.86B
Current Liabilities	$399.77M	$420.62M	$941.53M	$404.74M
Long-Term Debt	$1.54B	$1.54B	$991.42M	$994.92M
Total Debt	$1.59B	$1.59B	$1.58B	$1.04B
Total Liabilities	$2.04B	$2.07B	$2.03B	$1.47B
Retained Earnings	-$15.01B	-$15.23B	-$16.23B	-$16.43B
Shareholders' Equity	$2.31B	$2.33B	$1.49B	$1.39B
Working Capital	$915.62M	$1.07B	$722.37M	$714.39M
Net Debt	$617.11M	$415.01M	$243.81M	$213.84M

TDOC Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$189.29M	$350.02M	$293.68M	$294.36M
Capital Expenditure	-$172.76M	-$156.35M	-$124.05M	-$157.02M
Free Cash Flow	$16.53M	$193.67M	$169.63M	$137.33M
Depreciation & Amortisation	$267.78M	$348.72M	$382.84M	$376.43M
Stock-Based Compensation	$217.85M	$201.55M	$145.95M	$80.41M
Investing Cash Flow	-$167.74M	-$156.35M	-$124.05M	-$266.00M
Financing Cash Flow	$6.50M	$10.85M	$8.31M	-$551.65M
Net Change in Cash	$28.05M	$204.53M	$177.94M	-$523.30M

TDOC Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$631.90M	$626.44M	$642.27M	$613.85M	—
Cost of Revenue	$190.54M	$187.18M	$197.05M	$197.53M	—
Gross Profit	$441.36M	$439.26M	$445.22M	$416.32M	—
Research & Development	$68.78M	$67.57M	$71.61M	$67.86M	—
Selling, General & Admin	$325.61M	$318.77M	$305.74M	$304.90M	—
Operating Expenses	$487.40M	$474.72M	$472.19M	$465.05M	—
Operating Income	-$46.03M	-$35.46M	-$26.97M	-$48.73M	—
EBITDA	$58.94M	$46.46M	$70.55M	$38.71M	—
Pretax Income	-$40.42M	-$50.22M	-$33.62M	-$60.84M	—
Income Tax	-$7.76M	-$715.00K	-$8.47M	$3.00M	—
Net Income	-$32.66M	-$49.51M	-$25.14M	-$63.84M	—
Diluted EPS	-0.19	-0.28	-0.14	-10.80	-0.21
Diluted Shares	175.92M	176.93M	177.83M	5.97M	181.03M

TDOC Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$1.19B	$679.62M	$726.25M	$781.08M	$750.74M
Receivables	$243.23M	$234.00M	$219.48M	$201.66M	$222.54M
Inventory	$38.01M	$38.16M	$39.90M	$38.20M	$31.56M
Current Assets	$1.60B	$1.07B	$1.09B	$1.12B	$1.13B
Total Assets	$3.44B	$2.89B	$2.88B	$2.86B	$2.81B
Current Liabilities	$952.42M	$401.77M	$405.09M	$404.74M	$404.87M
Long-Term Debt	$992.29M	$993.16M	$994.04M	$994.92M	$995.81M
Total Debt	$1.59B	$1.04B	$1.04B	$1.04B	$1.04B
Total Liabilities	$2.02B	$1.47B	$1.49B	$1.47B	$1.47B
Retained Earnings	-$16.32B	-$16.36B	-$16.41B	-$16.43B	-$16.49B
Shareholders' Equity	$1.43B	$1.42B	$1.39B	$1.39B	$1.34B
Working Capital	$649.41M	$671.50M	$687.67M	$714.39M	$727.47M
Net Debt	$349.68M	$313.54M	$267.80M	$213.84M	$245.07M

TDOC Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$15.92M	$91.43M	$99.26M	$87.74M	$9.52M
Capital Expenditure	-$31.59M	-$59.80M	-$31.32M	-$34.32M	-$35.82M
Free Cash Flow	-$15.67M	$31.63M	$67.95M	$53.42M	-$26.31M
Depreciation & Amortisation	$90.17M	$94.89M	$92.15M	$99.22M	$94.19M
Stock-Based Compensation	$25.16M	$22.34M	$17.00M	$15.91M	$14.61M
Investing Cash Flow	-$123.27M	-$59.70M	-$48.72M	-$34.32M	-$36.52M
Financing Cash Flow	$769.00K	-$549.93M	-$3.59M	$1.10M	-$2.45M
Net Change in Cash	-$106.58M	-$518.20M	$46.95M	$54.53M	-$29.45M

Market Snapshot

About

Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company providing remote medical care services to patients. The company offers virtual care across multiple medical specialties including primary care, mental health, chronic condition management, and specialty care through its global platform. Teladoc serves millions of members worldwide through direct-to-consumer services and partnerships with employers, health plans, and health systems.